Tags

Type your tag names separated by a space and hit enter

Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma.
J Neurooncol. 1990 Feb; 8(1):61-5.JN

Abstract

The detection of hormone receptors on meningiomas raises the possibility of hormonal manipulation as a form of therapy. Since progesterone receptors are found on meningiomas more frequently and in greater amounts than estrogen receptors, manipulation of progesterone levels would be most promising. A trial of the oral progesterone agonist megestrol acetate for the treatment of unresectable meningioma was therefore performed. Megestrol acetate was administered at a dose of 40 mg four times daily which could be escalated to 80 mg four times daily. Nine patients (six meningothelial, two fibrous, and one anaplastic meningiomas) were treated for 1 to 12 months. No tumor responses were seen. However three patients required discontinuation of therapy due to deteriorating vision within 2 1/2 months. The major systemic toxicity of megestrol acetate was weight gain with a median weight gain of 14 kg for patients treated for at least 6 months. Due to the lack of efficacy and the significant toxicity noted, megestrol acetate is not recommended for the treatment of meningioma. However clinical trials of progesterone antagonists would still be of interest.

Authors+Show Affiliations

Division of Medical Oncology, LAC USC Medical Center, Los Angeles.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2319292

Citation

Grunberg, S M., and M H. Weiss. "Lack of Efficacy of Megestrol Acetate in the Treatment of Unresectable Meningioma." Journal of Neuro-oncology, vol. 8, no. 1, 1990, pp. 61-5.
Grunberg SM, Weiss MH. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol. 1990;8(1):61-5.
Grunberg, S. M., & Weiss, M. H. (1990). Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. Journal of Neuro-oncology, 8(1), 61-5.
Grunberg SM, Weiss MH. Lack of Efficacy of Megestrol Acetate in the Treatment of Unresectable Meningioma. J Neurooncol. 1990;8(1):61-5. PubMed PMID: 2319292.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. AU - Grunberg,S M, AU - Weiss,M H, PY - 1990/2/1/pubmed PY - 1990/2/1/medline PY - 1990/2/1/entrez SP - 61 EP - 5 JF - Journal of neuro-oncology JO - J. Neurooncol. VL - 8 IS - 1 N2 - The detection of hormone receptors on meningiomas raises the possibility of hormonal manipulation as a form of therapy. Since progesterone receptors are found on meningiomas more frequently and in greater amounts than estrogen receptors, manipulation of progesterone levels would be most promising. A trial of the oral progesterone agonist megestrol acetate for the treatment of unresectable meningioma was therefore performed. Megestrol acetate was administered at a dose of 40 mg four times daily which could be escalated to 80 mg four times daily. Nine patients (six meningothelial, two fibrous, and one anaplastic meningiomas) were treated for 1 to 12 months. No tumor responses were seen. However three patients required discontinuation of therapy due to deteriorating vision within 2 1/2 months. The major systemic toxicity of megestrol acetate was weight gain with a median weight gain of 14 kg for patients treated for at least 6 months. Due to the lack of efficacy and the significant toxicity noted, megestrol acetate is not recommended for the treatment of meningioma. However clinical trials of progesterone antagonists would still be of interest. SN - 0167-594X UR - https://www.unboundmedicine.com/medline/citation/2319292/Lack_of_efficacy_of_megestrol_acetate_in_the_treatment_of_unresectable_meningioma_ L2 - http://www.diseaseinfosearch.org/result/4595 DB - PRIME DP - Unbound Medicine ER -